KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) EBITDA Margin (2016 - 2025)

Boston Scientific (BSX) has disclosed EBITDA Margin for 17 consecutive years, with 15.61% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 81.0% to 15.61% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 18.0% through Dec 2025, up 245.0% year-over-year, with the annual reading at 18.0% for FY2025, 246.0% up from the prior year.
  • EBITDA Margin hit 15.61% in Q4 2025 for Boston Scientific, down from 20.69% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 20.69% in Q3 2025 to a low of 5.76% in Q4 2021.
  • Historically, EBITDA Margin has averaged 14.68% across 5 years, with a median of 15.1% in 2022.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 2091bps in 2021 and later crashed -223bps in 2024.
  • Year by year, EBITDA Margin stood at 5.76% in 2021, then soared by 115bps to 12.4% in 2022, then rose by 26bps to 15.68% in 2023, then fell by -6bps to 14.8% in 2024, then grew by 5bps to 15.61% in 2025.
  • Business Quant data shows EBITDA Margin for BSX at 15.61% in Q4 2025, 20.69% in Q3 2025, and 16.18% in Q2 2025.